Toni Choueiri, MD, of Dana-Farber Cancer Institute presents first results from the ARC-20 trial evaluating casdatifan (HIF-2 inhibitor) + cabozantinib (VEGF TKI) in metastatic clear cell kidney cancer.
Well, during the 2025 ESCO meeting, another stellar meeting for all our faculty at Dana-Farber, I had the chance as part of an oral presentation to present for the first time the combination of the egg FTKI proven kidney cancer cabozantinib, plus the H2 inhibitor Catifin. It's a new drug that, uh, uh, last year, um, we started the. Uh, presenting about single agent activity. This drug is not approved. Bezotifan is approved, but it's quite promising single agent activity, and as part of a trial by the name ARC-20, we took this to the next level. So we're exploring uh also a combination of this oral HIP2 inhibitor in metastatic clear cell kidney cancer a disease that is one of the top 10 cancers in the United States. So we saw a confirmed response rate over 45%. That would be higher than than single agent Cata defan. We saw that we could manage the toxicities and despite the short uh follow up on the patient, less than 6 months on average, the responses happen and happen fast, so this number may even go higher. We didn't see any unexpected toxicity and very low rate of patients who stopped therapy because of toxicity. So what is the next step? The next step in this combination, we call it Cascabo Cas the different cabos antonym is to take it to a phase 3 trial. In fact, there is a planned phase 3 trial by the name Peak one that hopefully will start enrolling in later this. year later 2025 that randomizes patients to Cascabo versus Cabo. This is in patients whose tumor have shown a growth on immune checkpoint inhibitor which we use as adjuvant therapy or first line kidney cancer. So these are very good news for kidney cancer patients always bringing new options here at Dana-Farber with many other collaborators across the world.
